| SKŘIČKOVÁ, Jana, Zbyněk BORTLÍČEK, Karel HEJDUK, Milos PESEK, Vitezslav KOLEK, Leona KOUBKOVA, Marketa CERNOVSKA, Marcela TOMÍŠKOVÁ, Jaromir ROUBEC, Libor HAVEL, Frantisek SALAJKA, Helena COUPKOVA, Michal HRNCIARIK, Milada ZEMANOVA, Dimka SIXTOVA, Monika ŠATÁNKOVÁ, Bohdan KADLEC a Miroslav MAREL. Gefitinib in Front-Line Treatment of 161 Caucasian Patients with NSCLC of the Czech Republic. In 16th World Conference on Lung Cancer. 2015. ISSN 1556-0864. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1320380,
author = {Skřičková, Jana and Bortlíček, Zbyněk and Hejduk, Karel and Pesek, Milos and Kolek, Vitezslav and Koubkova, Leona and Cernovska, Marketa and Tomíšková, Marcela and Roubec, Jaromir and Havel, Libor and Salajka, Frantisek and Coupkova, Helena and Hrnciarik, Michal and Zemanova, Milada and Sixtova, Dimka and Šatánková, Monika and Kadlec, Bohdan and Marel, Miroslav},
booktitle = {16th World Conference on Lung Cancer},
keywords = {advanced NSCLC; Targeted therapy; EGFR activated mutations; gefitinib},
language = {eng},
title = {Gefitinib in Front-Line Treatment of 161 Caucasian Patients with NSCLC of the Czech Republic},
year = {2015}
}
TY - CONF
ID - 1320380
AU - Skřičková, Jana - Bortlíček, Zbyněk - Hejduk, Karel - Pesek, Milos - Kolek, Vitezslav - Koubkova, Leona - Cernovska, Marketa - Tomíšková, Marcela - Roubec, Jaromir - Havel, Libor - Salajka, Frantisek - Coupkova, Helena - Hrnciarik, Michal - Zemanova, Milada - Sixtova, Dimka - Šatánková, Monika - Kadlec, Bohdan - Marel, Miroslav
PY - 2015
TI - Gefitinib in Front-Line Treatment of 161 Caucasian Patients with NSCLC of the Czech Republic
KW - advanced NSCLC
KW - Targeted therapy
KW - EGFR activated mutations
KW - gefitinib
N2 - growth factor receptor tyrosine kinase inhibitor. This study evaluates treatment outcomes in 161 NSCLC patients from Czech Republic according to activated mutations located in exons 19 and 21. Conclusion: In both groups of patients, the treatment was very safe. Median PFS and median OS were satisfactory without statistically significant differences between the two groups; however, a better trend was observed in the group of patients with mutations in exon 19. Consequently survival estimates shows great variability and longer potential follow up is needed to confirm these results.
ER -
SKŘIČKOVÁ, Jana, Zbyněk BORTLÍČEK, Karel HEJDUK, Milos PESEK, Vitezslav KOLEK, Leona KOUBKOVA, Marketa CERNOVSKA, Marcela TOMÍŠKOVÁ, Jaromir ROUBEC, Libor HAVEL, Frantisek SALAJKA, Helena COUPKOVA, Michal HRNCIARIK, Milada ZEMANOVA, Dimka SIXTOVA, Monika ŠATÁNKOVÁ, Bohdan KADLEC a Miroslav MAREL. Gefitinib in Front-Line Treatment of 161 Caucasian Patients with NSCLC of the Czech Republic. In \textit{16th World Conference on Lung Cancer}. 2015. ISSN~1556-0864.
|
